Certara (NASDAQ:CERT) Announces Earnings Results

Certara (NASDAQ:CERT) released its earnings results on Monday. The company reported $0.09 earnings per share for the quarter, missing the consensus estimate of $0.11 by ($0.02), Briefing.com reports. Certara had a negative net margin of 0.38% and a positive return on equity of 4.20%. The business’s revenue was up .8% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.14 EPS. Certara updated its FY 2026 guidance to 0.350-0.410 EPS.

Certara Stock Performance

NASDAQ:CERT opened at $6.31 on Monday. The company has a market capitalization of $967.45 million, a P/E ratio of -631.00 and a beta of 1.53. The stock’s 50 day moving average price is $6.25 and its 200 day moving average price is $8.11. The company has a debt-to-equity ratio of 0.27, a quick ratio of 2.05 and a current ratio of 2.05. Certara has a 52 week low of $5.19 and a 52 week high of $13.88.

Wall Street Analyst Weigh In

Several analysts recently commented on the stock. TD Cowen restated a “buy” rating on shares of Certara in a report on Thursday, February 26th. KeyCorp dropped their price objective on shares of Certara from $10.00 to $8.00 and set an “overweight” rating on the stock in a research note on Monday, April 13th. Barclays reiterated an “equal weight” rating and issued a $8.00 target price on shares of Certara in a research report on Friday, March 6th. Craig Hallum cut shares of Certara from a “buy” rating to a “hold” rating and set a $10.00 price target on the stock. in a report on Friday, February 27th. Finally, Wall Street Zen downgraded shares of Certara from a “buy” rating to a “hold” rating in a research note on Sunday, February 15th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, five have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $10.44.

Institutional Trading of Certara

Several large investors have recently added to or reduced their stakes in the business. Osaic Holdings Inc. raised its holdings in shares of Certara by 50.7% during the 2nd quarter. Osaic Holdings Inc. now owns 3,491 shares of the company’s stock valued at $41,000 after purchasing an additional 1,175 shares in the last quarter. Corient Private Wealth LLC boosted its holdings in Certara by 11.7% in the second quarter. Corient Private Wealth LLC now owns 12,362 shares of the company’s stock worth $144,000 after purchasing an additional 1,295 shares in the last quarter. Treasurer of the State of North Carolina boosted its holdings in Certara by 2.9% in the second quarter. Treasurer of the State of North Carolina now owns 56,628 shares of the company’s stock worth $663,000 after purchasing an additional 1,597 shares in the last quarter. Nicolet Advisory Services LLC increased its position in Certara by 7.4% during the third quarter. Nicolet Advisory Services LLC now owns 30,608 shares of the company’s stock worth $396,000 after buying an additional 2,100 shares during the last quarter. Finally, Amundi increased its position in Certara by 6.7% during the third quarter. Amundi now owns 45,708 shares of the company’s stock worth $615,000 after buying an additional 2,859 shares during the last quarter. 73.96% of the stock is owned by institutional investors.

Certara Company Profile

Certara is a biosimulation software and services company that partners with pharmaceutical, biotechnology and medical device developers to accelerate drug discovery, development and regulatory approval. The company’s platform integrates quantitative pharmacology, real-world evidence, artificial intelligence and machine learning to model and simulate drug behavior across a range of therapeutic areas and patient populations. By applying these mechanistic and data-driven approaches, Certara helps its clients predict clinical outcomes, optimize dosing strategies and streamline decision-making throughout the product lifecycle.

The company’s offerings are divided into software tools and consulting services.